None listed
Conditions
Interventions
Drug : Administer eflapegrastim 13.2mg subcutaneously once a month for a total of 4 doses.
Sponsors
Yonsei University Health System, Gangnam Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) at initial diagnosis. ? Patients with locally advanced or metastatic pancreatic cancer for whom surgery is not feasible. ? Patients aged 18 years or older.
Exclusion criteria
Exclusion criteria: ? Patients with a history of prior chemotherapy or radiation therapy. ? Patients who discontinued chemotherapy within 2 cycles. ? Patients with a follow-up duration of less than 2 months who have not undergone initial response evaluation. ? Recurrent pancreatic cancer following curative surgery. ? Patients with concurrent or suspected hematologic disorders. ? Patients who have undergone bone marrow or stem cell transplantation previously. ? Patients with autoimmune diseases. ? Patients taking steroids or immunosuppressive agents. ? Patients diagnosed with HIV/AIDS. ? Severe liver or kidney disease. ? Active double primary cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of severe neutropenia (grade III-IV), febrile neutropenia | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of chemotherapy, dose of chemotherapy, survival outcomes, duration of neutropenia, duration of admission due to neutropenic event, duration of antibiotics usage, incidence of infection(cholangitis, liver abscess), UGT1A1 subgroup analysis | — |
Countries
Korea, Republic of
Contacts
Public ContactJiyoung Keum
Ewha Womans University Medical Center
Outcome results
None listed